CAFs provide ovarian cancer cells resistance to cisplatin by secreting cisplatin-induced chemokine (C-C motif) ligand 5 (CCL5), which augments the phosphorylation of STAT3 and Akt in cancer cells. Here, CCL5 is linked to ovarian carcinoma.